Protheragen

Protheragen is a contract research organization dedicated to advancing preclinical research in obesity therapeutics. The company provides an integrated obesity research platform spanning discovery through preclinical testing, with expertise in metabolism, inflammation, and cardiovascular biology.

Core Preclinical Services:

• Obesity models that replicate obesity-related conditions
• Pharmacodynamic studies assessing biological effects and mechanisms of action
• Pharmacokinetic studies evaluating drug absorption, distribution, metabolism, and excretion
• Bioanalysis using advanced techniques to quantify drug concentrations in biological samples
• Safety assessment and toxicological evaluation in preclinical models
• Target selection and screening across multiple obesity-related pathways (leptin, GLP-1, MC4R, PPARs, CB1/CB2, and others)

Therapeutic Modalities Supported:

• Anti-obesity small molecule drug development
• Gene therapy development
• Cell therapy development
• Antibody therapy development
• Tissue engineering therapy development
• Nanotherapy development

Regulatory & Clinical Support:

• Regulatory affairs and submission support
• Clinical development strategy and medical writing
• Early phase clinical pharmacology services
• Clinical operations and trial management
• Data management and biostatistics
• Pharmacovigilance and risk management

Protheragen maintains GLP/GMP compliance and quality control standards to ensure regulatory acceptance of preclinical data. The company emphasizes collaborative, tailored approaches with flexible project management to accelerate client drug development timelines.